Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.39 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.39 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.38 |
| ▸ | ADH1C | P00326 | 1/20 | 0.38 |
| ▸ | ADH1A | P07327 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | ADH7 | P40394 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5595513 | 0.94 | FAAH (0.47) | FAAHADRB2PLA2G2AGPR84CA1 | |
| SCHEMBL5595691 | 0.94 | FAAH (0.47) | FAAHADRB2PLA2G2AGPR84CA1 | |
| SCHEMBL5595510 | 0.94 | FAAH (0.47) | FAAHADRB2PLA2G2AGPR84CA1 | |
| SCHEMBL4532260 | 0.92 | FAAH (0.50) | FAAHPLA2G2AGPR84ADH1BADH1C | |
| SCHEMBL6670003 | 0.92 | FAAH (0.50) | FAAHPLA2G2AGPR84ADH1BADH1C | |
| SCHEMBL9719708 | 0.92 | FAAH (0.50) | FAAHPLA2G2AGPR84ADH1BADH1C | |
| Hydrochloric Acid SCHEMBL5596146 | 0.92 | FAAH (0.46) | FAAHADRB2PLA2G2AGPR84CA1 | |
| SCHEMBL11371381 | 0.92 | FAAH (0.50) | FAAHPLA2G2AGPR84ADH1BADH1C | |
| Hydrochloric Acid SCHEMBL5596139 | 0.92 | FAAH (0.46) | FAAHADRB2PLA2G2AGPR84CA1 | |
| SCHEMBL9719704 | 0.92 | FAAH (0.50) | FAAHPLA2G2AGPR84ADH1BADH1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021526-B2 | DSG2-derived peptides | ASCLEPIUMM TAIWAN CO., LTD (TW) | 2021-06-01 | — | — | US | claimed |
| EP-3571216-B1 | APOC-II MIMETIC PEPTIDES | US HEALTH (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4745153-A1 | GLP-1, GIP AND GCG RECEPTOR TRIAGONIST AND USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| CN-120189496-B | Oral polypeptide composition | 深圳奥礼生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125664-A1 | COMPOSITIONS AND METHODS RELATING TO RECOMBINANT CHYMOTRYPSIN | PROMEGA CORP (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | UNIV CALIFORNIA (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2026090584-A2 | METHODS OF TREATING PERIPHERAL NERVOUS SYSTEM MYELINATION CONDITIONS | Artery Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4729094-A2 | Modulators of complement activity | UCB Holdings, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| EP-0966297-A1 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999040788-A1 | INOTROPIC AND DIURETIC EFFECTS OF EXENDIN AND GLP-1 | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999040928-A1 | NOVEL MIXED AMYLIN ACTIVITY COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999025727-A2 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999025728-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-05-27 | — | — | WO | disclosed |
| WO-1999007404-A1 | NOVEL EXENDIN AGONIST COMPOUNDS | AMYLIN PHARMACEUTICALS, INC. (US) | 1999-02-18 | — | — | WO | disclosed |
| WO-1998030231-A9 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE | — | 1998-11-12 | — | — | WO | disclosed |
| WO-1998030231-A1 | USE OF EXENDINS AND AGONISTS THEREOF FOR THE REDUCTION OF FOOD INTAKE | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-07-16 | — | — | WO | disclosed |
| WO-1998005351-A9 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | — | 1998-05-28 | — | — | WO | disclosed |
| WO-1998005351-A1 | METHODS FOR REGULATING GASTROINTESTINAL MOTILITY | AMYLIN PHARMACEUTICALS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125664-A1 | COMPOSITIONS AND METHODS RELATING TO RECOMBINANT CHYMOTRYPSIN | CMA1, PREP, TPSG1 | CA2 2407/4885MAPK1 859/4885FAAH 1175/4885 |
| US-20260124313-A1 | SITE-SPECIFIC COVALENT LIGATION OF HUMAN SERUM ALBUMIN | GLP1R, ALB, GIPR | CA2 2664/4885MAPK1 801/4885FAAH 602/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | CA2 4235/4885MAPK1 1763/4885FAAH 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.